In silico analysis of different generation β lactams antibiotics with penicillin binding protein-2 of Neisseria meningitidis for curing meningococcal disease

Serogroup diversity and antibiotic susceptibility of Neisseria meningitidis: Meningococcus infection monitoring in Belarus

This study performed an epidemiological survey of Neisseria meningitidis strains isolated from patients and from asymptomatic carriers. Altogether, 74 N. meningitidis strains (46 invasive and 28 non-invasive) were isolated between February 2011 and May 2018 in different regions of the Republic of Belarus. Serogenotyping was carried out by real-time PCR. Minimum inhibitory concentrations (MICs) of antibiotics were determined by broth microdilution and results were interpreted in accordance with EUCAST. The serogroups of N. meningitidis were determined as follows: serogroup B - 65%, C - 11%, W - 9%, A - 5%, Y - 4%, and Z and NG - 3% each. The MIC₅₀ and MIC₉₀ for benzylpenicillin (0.032/0.064-0.125 mg/L), ampicillin (0.032/0.125 mg/L), amoxicillin (0.125/0.25 mg/L), cefotaxime (0.016/0.016 mg/L), ceftriaxone (0.002/0.016 mg/L), ciprofloxacin (0.004/0.008 mg/L), chloramphenicol (1/1 mg/L), meropenem (0.008/0.008-0.016 mg/L), tetracycline (0.25/0.5 mg/L), and rifampicin (0.016/0.25 mg/L) were established. Strains with intermediate susceptibility for benzylpenicillin (12.3%), ampicillin (6.8%), and amoxicillin (24.7%) have been identified. In this study, we report the first rifampicin-resistant N. meningitidis in Belarus.

Design, synthesis, and structural elucidation of novel NmeNANAS inhibitors for the treatment of meningococcal infection

Neisseria meningitidis is the primary cause of bacterial meningitis in many parts of the world, with considerable mortality rates among neonates and adults. In Saudi Arabia, serious outbreaks of N. meningitidis affecting several hundreds of pilgrims attending Hajj in Makkah were recorded in the 2000–2001 season. Evidence shows increased rates of bacterial resistance to penicillin and other antimicrobial agents that are used in the treatment of the meningococcal disease. The host’s immune system becomes unable to recognize the polysialic acid capsule of the resistant N. meningitidis that mimics the mammalian cell surface. The biosynthetic pathways of sialic acid (i.e., N-acetylneuraminic acid [NANA]) in bacteria, however, are somewhat different from those in mammals. The largest obstacle facing previously identified inhibitors of NANA synthase (NANAS) in N. meningitidis is that these inhibitors feature undesired chemical and pharmacological characteristics. To better comprehend the binding mechanism underlying these inhibitors at the catalytic site of NANAS, we performed molecular modeling studies to uncover essential structural aspects for the ultimate recognition at the catalytic site required for optimal inhibitory activity. Applying two virtual screening candidate molecules and one designed molecule showed promising structural scaffolds. Here, we report ethyl 3-benzoyl-2,7-dimethyl indolizine-1-carboxylate (INLZ) as a novel molecule with high energetic fitness scores at the catalytic site of the NmeNANAS enzyme. INLZ represents a promising scaffold for NmeNANAS enzyme inhibitors, with new prospects for further structural development and activity optimization.